Floatz logo

VINBLASTINE

Transitional Cell Carcinoma of the Bladder

University of Southern CaliforniaSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

38 Active assets in the Transitional Cell Carcinoma of the Bladder cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB
Nivolumab
Nagoya University
Phase 3BB

View all 50 →

Same molecule, other indications

VINBLASTINE is also rated in:

renal pelvis/ureter urothelial carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
carcinoma of urethraDormant
BBB
Indicative ·
73 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →